Metacrine, Inc. (NASDAQ:MTCR – Get Rating) insider Michael York sold 107,054 shares of Metacrine stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $0.41, for a total value of $43,892.14. Following the completion of the transaction, the insider now owns 103,499 shares in the company, valued at $42,434.59. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Metacrine Price Performance
Shares of NASDAQ MTCR traded down $0.00 during mid-day trading on Friday, reaching $0.48. The company had a trading volume of 849,659 shares, compared to its average volume of 308,842. The company has a current ratio of 12.15, a quick ratio of 12.15 and a debt-to-equity ratio of 0.34. The stock has a market cap of $20.44 million, a PE ratio of -0.47 and a beta of -0.92. The company has a 50-day moving average price of $0.43 and a two-hundred day moving average price of $0.45. Metacrine, Inc. has a 1-year low of $0.30 and a 1-year high of $0.68.
Get Metacrine alerts:Metacrine (NASDAQ:MTCR – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). On average, equities analysts anticipate that Metacrine, Inc. will post -0.62 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "neutral" rating on shares of Metacrine in a report on Wednesday, November 16th.Hedge Funds Weigh In On Metacrine
Several large investors have recently made changes to their positions in MTCR. State Street Corp lifted its position in shares of Metacrine by 482.8% during the 2nd quarter. State Street Corp now owns 72,186 shares of the company's stock worth $36,000 after purchasing an additional 59,800 shares during the last quarter. Citadel Advisors LLC lifted its position in shares of Metacrine by 112.5% during the 3rd quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock worth $66,000 after purchasing an additional 72,306 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Metacrine during the 3rd quarter worth about $84,000. Bank of New York Mellon Corp acquired a new position in shares of Metacrine during the 1st quarter worth about $126,000. Finally, Bank of America Corp DE raised its holdings in Metacrine by 10.5% in the 1st quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares in the last quarter. Institutional investors and hedge funds own 34.28% of the company's stock.
About Metacrine
(Get Rating)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Featured Stories
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
